Health Policy 2021: COVID-19 pandemic, drug pricing, ACA reform and data privacy
Ending the pandemic is clearly the top public-health priority for the incoming Biden administration. Will action on drug pricing, ACA reform and data privacy follow?
Legal/Regulatory
Pandemic or no, pharma needs to push drug pricing dialogue
Although the world is still months away from a COVID-19 vaccine, it’s imperative that pharma companies have the conversation right now about the cost of innoculation.
Vaccine makers and lawmakers stress importance of accessible COVID-19 vaccine
Leaders from pharma companies developing COVID-19 vaccines appeared before Congress on Tuesday.
Senate Democrats call to provide a COVID-19 vaccine for free
In a white paper, Senate Democrats urge the Trump administration to ensure a COVID-19 vaccine is free for Americans.
Federal health officials appear before House committee to discuss coronavirus
Health leaders set the record straight on testing and outbreaks in recently reopened states.
Appeals court strikes down the rule requiring list prices in drug ads, again
A previous judge ruled that HHS did not have the authority to issue the rule.
FDA app allows doctors to share real-world COVID-19 information
The CureID app is also collaborating with the WHO and the Infectious Disease Society of America.
FDA partners with Aetion to gather real-world data on the coronavirus
The FDA continues its investment in real-world data with this partnership.
Pricing remdesivir: Will Gilead profit from the COVID-19 treatment?
As remdesivir emerges as an effective coronavirus treatment, how Gilead prices the drug will face heightened scrutiny.
Telehealth rules relaxed, but patients still face barriers
The government has relaxed telehealth rules as most people stay home to help flatten the curve, but patients still face barriers for virtual visits.
